Jefferies Downgrades Moonlake Immunotherapeutics (MLTX) to Hold, 'Growing Uncertainty in SLK Path Fwd and Dimmed Commercial Outlook'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/11/2026

1. ORCL
2. SPY
3. SPCX
4. USO
5. CHWY
6. NAVN
7. CME
8. HUMA
9. NVDA
10. CRWV

Go back to Jefferies Downgrades Moonlake Immunotherapeutics (MLTX) to Hold, 'Growing Uncertainty in SLK Path Fwd and Dimmed Commercial Outlook'

Moonlake Immunotherapeutics (MLTX) PT Lowered to $12 at Clear Street

September 29, 2025 4:38 PM EDT

Clear Street analyst Kaveri Pohlman lowered the price target on Moonlake Immunotherapeutics (NASDAQ: MLTX) to $12.00 (from $108.00) while maintaining a Buy rating.

The analyst comments "We believe COSENTYXs approvaleven without statistically significant results in one of its P3 trials (Sunshine)serves as an encouraging... More